Patients with advanced kidney cancer in the UK now have access to nivolumab through an early access scheme.
Patients with advanced renal cell carcinoma (RCC)—the 8th most common cancer in the UK—will now have access to nivolumab ahead of a licensing decision in Europe. UK’s Medicines and Healthcare Regulatory Products Agency announced the inclusion of nivolumab in the Early Access to Medicines Scheme, which lends patients access to drugs before they are officially approved.
Patients with RCC usually present with advanced disease when first diagnosed (27% in the UK), of which just 15% of men and 10% of women will survive for 5 years or more; this presents a huge unmet need in the population.
The international phase 3 trial of nivolumab in patients with RCC, Checkmate-025, recruited patients from across 24 countries. The trial was stopped early based on advice from an independent Data Monitoring Committee following results from the phase 3 study—a significant increase in median overall survival of 5.4 months was observed in previously-treated patients with RCC who were administered nivolumab, compared with those treated with everolimus
Nivolumab was only recently approved by the FDA for treating patients with advanced RCC who had progressed on prior therapy. When announcing the approval, Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research said, “Opdivo’s extended indication, from melanoma and non-small cell lung cancer to renal cell cancer, demonstrates how immune therapies can benefit patients across a wide range of tumors.”
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More